

Title: COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the dominant circulating variant— Zambia, December 2021

Authors: John Simwanza^{1,2}; Jonas Z. Hines³; Danny Sinyange^{1,2}; Nyambe Sinyange⁴; Chilufya Mulenga^{1,4}; Sarah Hanyinza⁴; Patrick Sakubita⁴; Nelia Langa⁴; Haggai Nowa⁵; Priscilla Gardner⁶; Ngonda Saasa⁷; Gabriel Chipeta⁶; James Simpungwe³; Warren Malambo³; Busiku Hamainza²; Nathan Kapata⁴; Muzala Kapina⁴; Kunda Musonda⁴; Mazyanga Liwewe⁴; Consity Mwale⁶; Sombo Fwoloshi⁹; Lloyd B. Mulenga⁹; Simon Agolory³; Victor Mukonka⁴; Roma Chilengi^{4,10};

Affiliations:

¹Zambia Field Epidemiology Training Programme, Lusaka, Zambia

²National Malaria Elimination Centre, Lusaka, Zambia

³Centers for Disease Control and Prevention, Lusaka, Zambia

⁴Zambia National Public Health Institute, Lusaka, Zambia

⁵Zambia Prison Services, Lusaka, Zambia

⁶Lusaka District Health Office, Lusaka, Zambia

⁷University of Zambia Veterinary Medicine Laboratory School, Lusaka, Zambia

⁸Lusaka Province Health Office, Lusaka, Zambia

⁹Ministry of Health, Lusaka, Zambia

¹⁰Republic of Zambia State House, Lusaka, Zambia

Keywords: COVID-19 vaccines, vaccine efficacy; SARS-CoV-2 variants, prisons, prisoners, Zambia, Africa

25

26 *Abstract:* During a COVID-19 outbreak in a prison in Zambia from 14th to 19th December
27 2021, a case control study was done to measure vaccine effectiveness (VE) against
28 infection and symptomatic infection, when the Omicron variant was the dominant circulating
29 variant. Among 382 participants, 74.1% were fully vaccinated and the median time since full
30 vaccination was 54 days. There were no hospitalizations or deaths. COVID-19 VE against
31 any SARS-CoV-2 infection was 64.8% and VE against symptomatic SARS-CoV-2 infection
32 was 72.9%. COVID-19 vaccination helped protect incarcerated persons against SARS-CoV-
33 2 infection during an outbreak while Omicron was the dominant variant in Zambia.

34

35

36

37

38 *Introduction*

39 COVID-19 continues to ravage the globe as new SARS-CoV-2 variants emerge and cause
40 new waves of infections. The highly transmissible Omicron variant emerged in late 2021,
41 rapidly spreading to many countries and leading to record-breaking case counts globally. In
42 early December 2021, Zambia recorded a rapid rise in confirmed COVID-19 cases,
43 coinciding with confirmation of the Omicron variant in the country. Zambia recorded a daily
44 average of 1,422 confirmed COVID-19 cases in December 2021, compared to an average
45 15 cases daily the previous month, in November 2021. From December 4th to 24th, 2021, all
46 sequenced specimens in Zambia were of the Omicron variant (1).

47 Congregate living settings, including prisons, are at high risk for COVID-19 outbreaks (2).
48 Congested living conditions make physical distancing and avoidance of crowds challenging
49 in many prison settings. Although difficult to enforce, use of face masks in high SARS-CoV-2
50 transmission risk settings can limit the rapid spread of infection (3).

51 On December 14th, 2021, after not recording any COVID-19 cases for months, a local prison
52 in Lusaka noted an increase in the number of residents with respiratory symptoms, 19 of
53 whom tested positive for COVID-19 with rapid diagnostic tests (RDTs). The prison notified
54 the Lusaka District Health Office on the same day and an outbreak investigation was
55 initiated. Mitigation measures were reinforced, including mask distribution and mandatory
56 masking, cohorting persons testing positive and provision of hand hygiene stations
57 throughout the prison. Of 767 persons incarcerated at the facility during the outbreak, 241
58 (31.4%) tested positive for COVID-19 from December 14th to 19th, 2021.

59 COVID-19 vaccines have shown remarkable effectiveness, particularly for reducing COVID-
60 19 severity (4). COVID-19 vaccine effectiveness (VE) against the Omicron variant is lower
61 than against other variants (5,6), although data from the African continent are limited (7–9).
62 Correctional services in Zambia achieved high COVID-19 vaccine coverage among
63 incarcerated persons prior to the Omicron variant wave through onsite vaccination clinics

64 and enhanced COVID-19 screening and testing with encouragement of vaccination for those
65 testing negative. Of the incarcerated persons at this local prison, 619 (80.7%) were
66 vaccinated when the outbreak occurred (compared to 12.6% of the eligible general
67 population in Zambia at the time). We measured VE among incarcerated persons during
68 this outbreak in Zambia.

69

70 *Methods*

71 A case-control study of SARS-CoV-2 infection and symptomatic infection by vaccination
72 status was conducted among persons incarcerated at the prison facility during the outbreak
73 from 15th to 20th December 2021. The facility is in Lusaka, the national capital of Zambia,
74 and houses men aged ≥ 13 years awaiting court cases or transfer to other prisons after
75 sentencing. The prison has five cells built to house 92 persons, although at the outbreak
76 onset 767 persons were incarcerated (i.e., > 800% beyond capacity).

77 During the outbreak, all incarcerated persons were tested for COVID-19 using Panbio
78 COVID-19 Ag rapid test (Abbott Rapid Diagnostics Jena GmbH, Germany) from December
79 14th to 19th, 2021. Cases and controls were incarcerated persons testing COVID-19 positive
80 and negative, respectively. Participants were recruited into the study between December
81 20th to 24th, 2021 by reviewing the outbreak line list maintained by the prison health team
82 and district health office, attempting to frequency match controls by cases' cell assignment.
83 Verbal consent was obtained from the participants, and for minors aged 13–17 years
84 consent was obtained from the prison warden as per Zambia Correctional Services policy.
85 This study was approved by the ERES Ethics review board and National Health Research
86 Authority. The activity was reviewed by US Centers for Disease Control and Prevention and
87 was conducted consistent with applicable Federal law and CDC policy.

88 A standardized questionnaire that included information on demographics and medical
89 history, including COVID-19 vaccination and test results was administered by trained

interviewers. Self-reported COVID-19 test results were confirmed with the line list where the RDT results were recorded. Vaccination status was cross-referenced with the national registry.

Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥ 14 days before COVID-19 testing. Partial vaccination was defined as having received the 1st dose of a two-dose vaccine ≥ 14 days before COVID-19 testing but not the 2nd dose yet or receiving the 2nd dose ≤ 13 days before testing. Persons who were partially vaccinated or indeterminate status (i.e., received their 1st dose of the One dose vaccine 0-13 days before testing, or had an unknown type of COVID-19 vaccine) were excluded from analyses. Multivariable logistic regression was used to calculate the odds of SARS-CoV-2 infection and symptomatic infection, adjusting for age, number of comorbidities, jail cell, and self-reported mask use. VE was calculated as 1 minus the adjusted odds ratio times 100. To reduce the risk of misclassification bias related to false negative RDT test results, we conducted a sensitivity analysis excluding symptomatic controls.

105

106 *Results*

In total, 385 (50.2%) of the 767 incarcerated persons present during the outbreak were reached for interview and 382 (49.8%) consented to being enrolled in the study. All were males, with a median age of 28 years (interquartile range [IQR]: 21-36 years) (Table 1). Overall, 84 (22.0%) had at least one comorbidity, with HIV being most common (n = 40, 10.5%). Only 16 (4.1%) reported having had COVID-19 previously.

Overall, 294 (77.0%) participants received ≥ 1 COVID-19 vaccine dose; of these 283 (96.3%) were fully vaccinated, 1 (0.3%) partially vaccinated and 10 (3.4%) indeterminate. Among fully vaccinated participants, 253 (89.4%) received the one-dose Janssen vaccine and 30 (10.6%) received the two-dose AstraZeneca vaccines. None had received an additional

(‘booster’) vaccine dose. The median time since receipt of a full primary vaccine series was 54 days (IQR: 28-85 days).

There were 180 (47.1%) COVID-19 positive incarcerated persons (i.e., cases) and 202 (52.9%) COVID-19 negative persons (i.e., controls). Among positive cases, 117 (65.0%) were in fully vaccinated persons (i.e., breakthrough infections). Of the 16 (4.1%) persons reporting prior confirmed COVID-19, 5 (29.4%) were positive during the outbreak (i.e., reinfections).

Overall, 104 (27.2%) persons reported any COVID-19 symptoms, with a greater proportion among cases (45.6% vs. 10.9%; $p < 0.01$, chi-square test). The most common symptoms among COVID-19 cases were cough (37.8%), rhinorrhoea (20.6%), headache (17.2%), and myalgias (12.8%) (Table 1). Eighty-nine (49.4%) of the 180 participants with cases sought medical care at the prison clinic, and none (0%) were admitted or died. Cases were more likely to have sought health care (49.4% vs. 8.4%, $p < 0.01$, chi-square test). There were no differences among the cases and controls in terms of age, number of comorbidities, prior Covid-19, or mask use.

Cases were less likely to be fully vaccinated than controls (65.0% versus 82.2%; $p < 0.01$, chi-square test) (Table 2). VE against SARS-CoV-2 infection was 64.8% (95% confidence interval [CI]: 36.1-81.0%) and VE against symptomatic SARS-CoV2 infection was 72.9% (95% CI: 42.0-87.5%). VE was higher for those vaccinated within the past 60 days compared to >60 days before COVID-19 testing, although the confidence intervals overlapped (VE for SARS-CoV-2 infection: 74.6% [95% CI: 50.3-87.4%] vs. 54.2% [95% CI: 6.9-77.9%], respectively). VE of Janssen vaccine against SARS-CoV-2 infection was 63.6% (95% CI: 33.6-80.5%) and against symptomatic infection was 73.0% (95% CI: 41.6-87.7%). VE of AstraZeneca against SARS-CoV-2 infection was 89.4% (95% CI: 59.5-97.8%) and against symptomatic infection was 85.1% (95% CI: 19.5-98.0%). The sensitivity analysis excluding symptomatic controls did not meaningfully change the VE estimates (VE against SARS-CoV-

2 infection was 64.1% [95% CI: 35.8-80.2%] and VE against symptomatic SARS-CoV2 infection was 73.4% [95% CI: 44.6-87.4%]). Forty persons (10.5%) in the analysis reported being HIV positive, among whom 77.3% of cases were vaccinated compared to 94.4% of controls ($p = 0.20$, chi-square test). Among PLHIV, VE against SARS-CoV-2 infection was 82.2% (95% CI: -107.0-99.4%).

Discussion

During a prison COVID-19 outbreak in Zambia, COVID-19 vaccination protected against SARS-CoV-2 infection and symptomatic illness while Omicron was the dominant strain in the country (1). These findings provide important evidence that might help increase COVID-19 vaccination in Zambia, where many more Zambians need to be vaccinated to reach the African Union targets adopted by the country (10).

The SARS-CoV-2 Omicron variant contains numerous mutations to the spike protein which may lead to immune evasion. VE estimates reported here are lower compared to prior strains (11,12), and the high proportion of breakthrough infections in this outbreak supports in theory the possibility of immune evading capability of Omicron. In this study, VE was higher for symptomatic illness than any infection; VE for severe illness could not be accessed because no persons were hospitalized or died during this outbreak although other studies have demonstrated durability against this important outcome (13). Similarly, VE of a booster dose could not be assessed because Zambia did not begin offering a booster dose until January 2022. The relatively short time since vaccination might explain the relatively higher effectiveness findings against Omicron (6,14,15). However, there was a suggestion of waning immunity when comparing the VE point estimates of participants fully vaccinated over two months before the outbreak with those vaccinated within the past two months. These findings are encouraging considering alarm raised early in the Omicron wave about

the vaccines widely available in Africa being ineffective against reducing SARS-CoV-2 transmission (16).

Notably, symptomology was mild among participants, which is consistent with reports from other countries that experienced Omicron surges (9,17). Animal evidence suggests this might be related to tropism of Omicron for upper respiratory epithelium relative to the lower respiratory tract (18). This finding might also reflect the relatively younger age of persons in this outbreak. The role of pre-existing immunity in Zambia from natural infection remains uncertain and serosurveys would be useful to understand to what proportion of people in Zambia have been infected with SARS-CoV-2.

This study had several limitations. All cases were confirmed with RDTs, which have lower sensitivity than PCR tests (19). Additionally, beyond initial test results, serial testing was not available meaning some controls might have been in their incubation period at the time of testing and therefore misclassified. Omicron was not confirmed by genomic sequencing in this outbreak, meaning the outbreak could have been from another strain; however, Omicron was already dominant in Zambia before this outbreak occurred (20). Lastly, although few participants reported a prior confirmed SARS-CoV-2 infection, the actual number might be much higher considering only a small proportion of cases are confirmed in Zambia (21).

Rapid investigation of an outbreak in a closed setting demonstrated VE of COVID-19 vaccines against Omicron infection in Zambia. COVID-19 vaccination remains a critical tool in decreasing SARS-CoV-2 transmission and severity especially when coupled with a layered prevention including well-fitting facemask use, hand hygiene, limiting large gatherings, and adequate ventilation and/or outdoor gatherings. Continuing to rapidly scale COVID-19 vaccination to all eligible persons in Zambia can help prevent SARS-CoV-2 transmission and symptomatic COVID-19.

193

194 *Attribution of Support.* This work has been supported by the President's Emergency Plan for
195 AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) and
196 the CDC Emergency Response to the COVID-19 pandemic.

197

198 *Disclaimer.* The findings and conclusions in this report are those of the author(s) and do not
199 necessarily represent the official position of the funding agencies. Use of trade names is for
200 identification only and does not imply endorsement by the funding agencies.

201

202 *References*

- 203 1. GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from:
204 <https://www.epicov.org/epi3/frontend#220b8c>
- 205 2. Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of
206 SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a
207 Federal Prison — Texas, July–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021
208 Sep;70(38):1349–54.
- 209 3. Centers for Disease Control and Prevention (CDC). Science Brief: Community Use of
210 Masks to Control the Spread of SARS-CoV-2 [Internet]. December 6, 2021. [cited
211 2022 Mar 5]. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html)
212 [ncov/science/science-briefs/masking-science-sars-cov2.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/masking-science-sars-cov2.html)
- 213 4. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
214 COVID-19 vaccines: a literature review and meta-analysis. *Int J Infect Dis*. 2022
215 Jan;114:252–60.
- 216 5. Andrews N, Stowe J, Kirsebom F, Toffa S, Rikeard T, Gallagher E, et al.
217 Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of
218 concern. *medRxiv* [Internet]. 2021 Dec;2021.12.14.21267615. Available from:
219 <https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1%0Ahttps://www.m>
220 [edrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract](https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1.abstract)
- 221 6. Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA
222 Vaccines Against COVID-19—Associated Emergency Department and Urgent Care
223 Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron
224 Variant Predominance — VISION Network, 10 States, August 2021—. *Morb Mortal*
225 *Wkly Rep* [Internet]. ePub: 21 J. Available from:
226 [https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#sugg](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation)
227 [estedcitation](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcitation)

- 228 7. Grey GE, Collie S, Garrett N, Goga A, Champion J, Zylstra M, et al. Vaccine
229 effectiveness against hospital admission in South African health care workers who
230 received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave:
231 Preliminary Results of the Sisonke 2 Study. medRxiv [Internet]. Available from:
232 <https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1>
- 233 8. Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al.
234 Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa
235 (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation
236 study. Lancet (London, England). 2022 Mar;399(10330):1141–53.
- 237 9. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2
238 Vaccine against Omicron Variant in South Africa. Vol. 386, The New England journal
239 of medicine. 2022. p. 494–6.
- 240 10. World Health Organization (WHO). Leaders Make Urgent Call To Accelerate
241 Vaccination Globally And In Africa [Internet]. Geneva, Switzerland; Available from:
242 [https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-](https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-vaccination-globally-and-in-africa)
243 [vaccination-globally-and-in-africa](https://www.who.int/news/item/14-09-2021-leaders-make-urgent-call-to-accelerate-vaccination-globally-and-in-africa)
- 244 11. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al.
245 Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &
246 Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without
247 Immunocompromising Conditions — United States, March–August 2021. MMWR
248 Morb Mortal Wkly Rep. 2021 Sep;70(38):1337–43.
- 249 12. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of
250 Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan;
- 251 13. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al.
252 Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive
253 Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR

254 Morb Mortal Wkly Rep. 2022 Mar;71(12):459–65.

255 14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rikeard T, Gallagher E, et al. Covid-19
256 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022
257 Apr;386(16):1532–46.

258 15. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning
259 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated
260 Emergency Department and Urgent Care Encounters and Hospitalizations Among
261 Adults During Periods of Delta and Omicron Variant Predominance - VISION Network,
262 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022
263 Feb;71(7):255–63.

264 16. Nolen S. Most of the World's Vaccines Likely Won't Prevent Infection From Omicron.
265 The New York Times [Internet]. Available from:
266 <https://www.nytimes.com/2021/12/19/health/omicron-vaccines-efficacy.html>

267 17. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics
268 and Outcomes of Hospitalized Patients in South Africa During the COVID-19
269 Omicron Wave Compared With Previous Waves. JAMA. 2021 Dec;

270 18. Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, et al. SARS-CoV-2
271 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta
272 variants strains in a mouse model of severe COVID-19. bioRxiv. 2021
273 Dec;2021.12.26.474085.

274 19. Akingba OL, Sprong K, Marais G, Hardie DR. Field performance evaluation of the
275 PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant
276 in the Eastern Cape, South Africa. J Clin Virol Plus [Internet]. 2021;1(1–2):100013.
277 Available from: <https://doi.org/10.1016/j.jcvp.2021.100013>

278 20. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel

279 coronavirus - Africa_Zambia-focused subsampling [Internet]. [cited 2022 Feb 16].
 280 Available from: <https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia>
 281 21. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence
 282 of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster
 283 sample survey. Lancet Glob Heal. 2021;(21):1–9.
 284
 285

286 Table 1. Characteristics and outcomes of cases and controls during an COVID-19 outbreak
287 in a prison in Zambia, December 2021

Variable	Cases* (N=180)	Controls* (N=202)	p-value [†]
Age, median years (IQR)	27 (21-36)	28 (21-36)	0.58
Imprisonment duration, median days (IQR)	41 (13-96)	43 (17-120)	0.79
Education level, n (%)			
None	5 (2.8)	5 (2.5)	0.34
Primary	68 (37.8)	63 (31.2)	
Secondary	82 (45.6)	111 (55)	
Tertiary	25 (13.9)	23 (11.4)	
Nationality, n (%)			
Zambian	143 (79.4)	176 (87.1)	0.06
Other	37 (20.6)	26 (12.9)	
Any comorbidity, n (%) [‡]	38 (21.1)	46 (22.8)	0.79
Comorbidity type, n (%)			
HIV	22 (12.2)	18 (8.9)	0.38
Hypertension	9 (5.0)	5 (2.5)	0.30
Cardiac disease	2 (1.1)	4 (2.0)	0.79
Diabetes	1 (0.6)	5 (2.5)	1.00
Renal disease	2 (1.1)	2 (1.0)	0.92
Pulmonary disease	1 (0.6)	1 (0.5)	1.00
Tuberculosis	1 (0.6)	2 (1.0)	1.00
Liver disease	1 (0.6)	1 (0.5)	1.00
Other	6 (3.4)	14 (7.1)	0.18
Prior COVID-19, n (%)	5 (2.8)	11 (5.4)	0.13
Mask use			
Always or most of the time	97 (53.9)	106 (52.5)	0.14
Sometimes or rarely	51 (28.3)	72 (35.6)	
Don't use a mask	32 (17.8)	24 (11.9)	
Timing of 1st Vaccine Dose, n (%)			
≥14 days before testing	118 (65.0)	168 (83.2)	<0.01
0-13 days before testing [¶]	4 (2.2)	4 (2.0)	
After testing	0 (0.0)	0 (0.0)	
Not vaccinated	58 (32.2)	30 (14.9)	
Vaccine type (n = 294), n (%)			
Janssen (J&J)	110 (90.2)	151 (87.8)	0.75
AstraZeneca	11 (9.0)	20 (11.6)	
Not known	1 (0.8)	1 (0.6)	
Vaccination status, n (%) ^{**}			
Fully	117 (65.0)	166 (82.2)	<0.01
Partially	0 (0.0)	1 (0.5)	
Indeterminate	5 (2.8)	5 (2.5)	
Unvaccinated	58 (32.2)	30 (14.9)	

Time since vaccination, median days (IQR)	56 (33-91)	53 (27-84)	0.02
Symptomatic, n (%)	82 (45.6)	22 (10.9)	<0.01
Symptoms, n (%)			
Cough	68 (37.8)	18 (8.9)	1.00
Rhinorrhea	37 (20.6)	6 (3.0)	0.21
Headache	31 (20.6)	6 (3.0)	0.51
Myalgia	23 (12.8)	2 (1.0)	0.12
Fever	18 (10.0)	3 (1.5)	0.57
Fatigue	10 (5.6)	1 (0.5)	0.52
Sore throat	9 (5.0)	6 (3.0)	1.00
Chills	6 (3.3)	2 (1.0)	1.00
Sinus congestion	3 (1.7)	1 (0.5)	NC
Loss of taste	2 (1.1)	0 (0.0)	NC
Loss of smell	2 (1.1)	0 (0.0)	NC
Others	5 (2.8)	2 (1.0)	NC
Sought health care, n (%)	89 (49.4)	17 (8.4)	<0.01
Admitted to hospital, n (%)	0 (0.0)	0 (0.0)	NC
Died, n (%)	0 (0.0)	0 (0.0)	NC

* Cases were participants with a positive SARS-CoV-2 rapid diagnostic test (RDT) results and controls were participants with a negative RDT result

† Student's t-test for continuous variables and chi-square test or Fischer exact test (where any cell size <10) for categorical variables

‡ Comorbidities included: hypertension, cardiac disease, obesity, pulmonary disease, kidney disease, liver disease, diabetes, cancer, HIV, and tuberculosis (current or past)

¶ Participants classified as indeterminate because immune status at time of testing was unknown

** Partial vaccination was defined as having received the 1st dose of a two-dose vaccine ≥14 days before COVID-19 testing but not the second dose or the 2nd dose ≤13 days before testing. Full vaccination was defined as having received the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days before COVID-19 testing. Persons who were vaccinated with their 1st dose 0-13 days before testing were considered to have indeterminate vaccination status and excluded from analyses.

IQR: interquartile range; NC: not calculated

288

289

290 Table 2. COVID-19 vaccine effectiveness against Omicron variant – Zambia, December 2021

Vaccination status	Fully vaccinated, n (%)		Vaccine effectiveness, % (95% CI)*	
	Cases	Controls	SARS-CoV-2 infection	Symptomatic infection
Vaccine brand [†]				
Any vaccine (n = 371)	117 (66.9)	166 (84.7)	64.8 (36.1-81.0)	72.9 (42.0-87.5)
Janssen (n = 341)	106 (64.6)	147 (83.1)	63.6 (33.6-80.5)	73.0 (41.6-87.7)
AstraZeneca (n = 118)	11 (15.9)	19 (38.8)	89.4 (59.5-97.8)	85.1 (19.5-98.0)
Vaccination timing [†]				
≤60 days (n = 249)	59 (50.4)	102 (77.3)	74.6 (50.3-87.4)	83.7 (60.8-93.6)
>60 days (n = 210)	58 (50.0)	64 (68.1)	54.2 (6.9-77.9)	53.2 (-16.6-81.6)

* Adjusted for age, number of comorbidities, jail cell, and mask use
[†] Analyses presented for fully vaccinated persons only. One person was partially vaccinated and 10 were indeterminate vaccination status (i.e., vaccinated with their 1st dose 0-13 days before COVID-19 testing)
CI: confidence interval

